Eric J. Sundberg, PhD, is the School of Medicine Endowed Professor and Chair of Biochemistry at the Emory University School of Medicine and an internationally recognized expert in antibody engineering, immune modulation, and protein–glycan interactions. His research has defined core principles governing IgG Fc structure–function relationshipJeffrey V. Ravetch, M.D., Ph.D. Theresa and Eugene Lang Professor, Rockefeller University; Head Leonard Wagner Laboratory of Molecular Genetics and Immunology.

B.S. 1973 Yale (Donald Crothers); Ph.D. 1978 Rockefeller University (Norton Zinder, Peter Model); M.D. 1979 Cornell Medical School; Postdoctoral studies 1979-1982 NIH (Phil Leder) 1982-1996 Member, Memorial Sloan-Kettering Cancer Center.

His laboratory has focused on the Fc domain of antibodies and its receptors (FcRs), establishing the pre-eminence of FcR pathways in host defense, inflammation and tolerance, describing novel signaling pathways. His work has been widely extended into clinical applications for the treatment of neoplastic, inflammatory and infectious diseases.

Awards: Burroughs-Wellcome Scholar Award, Pew Scholar Award, Boyer Award, NIH Merit Award, Lee C. Howley, Sr. Prize (2004), AAI-Huang Foundation Meritorious Career Award (2005), William B. Coley Award (2007), Sanofi-Pasteur Award (2012), Gairdner International Prize (2012), Wolf Prize in Medicine (2015), Ross Prize in Molecular Medicine (2017), Robert Koch award (2018), William Paul Memorial Award (2021) and Cooper Prize in Immunology (2025). He received an honorary doctorate from Freidrich-Alexander University, Nuremberg/Erlangen and is a member of National Academy of Sciences (2006), the Institute of Medicine (2007), a Fellow of the American Academy of Arts and Sciences (2008) and a Fellow of the American Association for the Advancement of Science (2009).

Ravetch served as a member of the Scientific Advisory Boards of the Cancer Research Institute, the Irvington Institute for Medical Research, the Damon Runyon Foundation, the medical advisory board of Gairdner Foundation, the Sanofi-Pasteur Award Jury and the L’Oreal Women in Science Jury. He has been active in biotechnology for the last three decades, founding 5 biotechnology companies and currently serves as a member of the Scientific Advisory Boards of Biohaven, Jasper, Nuvig, Rhapsogen and Vir .s, glycosylation-dependent control of antibody-mediated effector functions, and enzymatic remodeling of antibodies.

Dr. Sundberg’s laboratory has made foundational discoveries in IgG-specific endoglycosidases and Fc glycoengineering, revealing previously unrecognized mechanisms of antibody asymmetry and epistasis that directly inform the design of next-generation biologics. These insights have translated into novel therapeutic modalities, including antibody-editing enzymes and engineered antibodies with precisely tuned immune functions.

He is a co-founder and/or board member of multiple biotechnology companies and holds an extensive patent portfolio licensed for clinical development. Dr. Sundberg brings deep experience in translational strategy and mechanism-driven product differentiation, bridging fundamental science and scalable therapeutic innovation.